GHRH Antagonist Suppresses Human Endometrial Cancer Cell Invasion by Down-regulating Twist and N-cadherin
Background
More than 25% of patients with endometrial carcinoma face invasive primary cancer and metastases, highlighting a critical need for novel therapeutic strategies. Current treatments often fall short in managing advanced, metastatic disease. While Growth Hormone-Releasing Hormone (GHRH) is known for its role in reproduction, its involvement in cancer progression, particularly in endometrial cancer cell motility and invasion, is an emerging area of research. Targeting the GHRH receptor with antagonists offers a potential pathway to inhibit cancer spread.
Study Design
Researchers investigated the effects of a GHRH antagonist on human endometrial cancer cells in vitro. Cell motility was assessed using invasion and migration assays after treatment with the GHRH antagonist in a dose-dependent manner. The expression levels of GHRH receptor, Twist, and N-cadherin proteins were determined via Western blotting and immunohistochemistry (IHC). To elucidate the mechanism, GHRH receptor siRNA, Twist siRNA, and N-cadherin siRNA were employed to knockdown specific genes in the cancer cells.
Results
The GHRH antagonist significantly inhibited human endometrial cancer cell motility in a dose-dependent manner. This effect was accompanied by a clear suppression of Twist and N-cadherin protein expression. Importantly, the observed inhibition of cell motility and the suppression of Twist and N-cadherin expression were completely abolished by GHRH receptor siRNA pretreatment, confirming the critical role of the GHRH receptor in mediating these effects. Furthermore, direct inhibition of Twist and N-cadherin using their respective siRNAs independently suppressed cell motility, validating their involvement in cancer cell invasiveness. This indicates a novel mechanism where GHRH antagonism reduces cancer cell spread. The GHRH antagonist inhibited cell motility and suppressed the expression of Twist and N-cadherin, with this suppression being abolished by GHRH receptor siRNA pretreatment.
Key Findings
- A GHRH antagonist dose-dependently inhibited human endometrial cancer cell motility in vitro.
- The GHRH antagonist suppressed the expression of Twist and N-cadherin proteins.
- Inhibition of cell motility and Twist/N-cadherin suppression were abolished by GHRH receptor siRNA pretreatment.
- Direct Twist siRNA and N-cadherin siRNA knockdown independently suppressed cell motility.
Why It Matters
GHRH antagonists represent a promising new therapeutic strategy for invasive human endometrial cancer, potentially mitigating metastasis by targeting the GHRH receptor and downstream Twist/N-cadherin pathways. This research identifies a novel mechanism, offering a specific target for drug development beyond current standards of care. While currently an in vitro finding, it lays crucial groundwork for future preclinical animal studies and eventually clinical trials, aiming to improve outcomes for patients with advanced disease. This mechanism could lead to new treatment protocols for aggressive forms of endometrial cancer.
ghrh-antagonist
endometrial-cancer
cancer
cell-motility
in-vitro
twist